NEW YORK, Jan. 31, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that the company’s Board of Directors has decided to continue development of AST-915, an orally delivered treatment for essential tremor. This decision was made following the announcement of favorable clinical results from a Phase 1/2 clinical study of AST-915 conducted by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement between the NIH and Ariston Pharmaceuticals, Inc., a wholly owned subsidiary of Manhattan Pharmaceuticals, Inc. Data from this study, previously announced on December 16, 2010, demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power. The company intends to continue to work with the NIH and to proceed toward Phase 2 with the AST-915 development program.
